Please assess the completion status of the following clinical trial:

Trial Title: A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Plaque psoriasis involving up to 2 to 20% Body Surface Area~Exclusion Criteria:~* Lesions solely involving intertriginous areas, the scalp or the face~* Systemic therapy for their psoriasis~* Pustular psoriasis or erythroderma~* Currently on other topical agents or Ultraviolet B (UVB) therapy within 2 weeks of the first dose of study medication~* Started or discontinued therapy within 2 months of Screening with agents that can exacerbate psoriasis~* Receiving systemic triazole antifungals except fluconazole

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vehicle Cream (Type: PLACEBO_COMPARATOR): Vehicle cream, applied topically, once daily from Day 1 to Week 12.
- Ruxolitinib Phosphate 0.5% Cream (Type: EXPERIMENTAL): Ruxolitinib phosphate 0.5% cream, applied topically, once daily from Day 1 to Week 12.
- Ruxolitinib Phosphate 1.0% Cream (Type: EXPERIMENTAL): Ruxolitinib phosphate 1.0% cream, applied topically, once daily from Day 1 to Week 12.
- Ruxolitinib Phosphate 1.5% Cream (Type: EXPERIMENTAL): Ruxolitinib phosphate 1.5% cream, applied topically, once daily from Day 1 to Week 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).